Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reconsidering adjuvant immunotherapy for tuberculosis.

Robert S Wallis1

  • 1PPD, Washington, DC, USA. robert.wallis@columbia.ppdi.com

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|June 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A proteome-wide atlas of humoral immunity to <i>Mycobacterium tuberculosis</i> across the spectrum of disease.

Frontiers in immunology·2026
Same author

Deep learning approach for probabilistic pulmonary function estimation from chest X-ray and peak expiratory flow rate.

Communications medicine·2026
Same author

Interventions to reduce the impact of post-tuberculosis lung disease: a scoping review of the literature.

BMC pulmonary medicine·2026
Same author

Statins for polycystic ovary syndrome in varying resource settings: a phenome-wide association study and evidence synthesis.

Frontiers in pharmacology·2025
Same author

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.

The Lancet. Infectious diseases·2025
Same author

Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.

The Lancet. Infectious diseases·2025

Shortened tuberculosis (TB) treatment requires disrupting granulomas that shield bacteria. Anti-tumor necrosis factor (TNF) therapies show promise in accelerating TB treatment and reducing relapse risk by targeting these protective structures.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Pulmonary Medicine

Background:

  • Pulmonary tuberculosis (TB) treatment requires prolonged regimens to prevent relapse.
  • Relapse is often linked to persistent, semidormant infection within granulomas.
  • Shortened TB treatment regimens are crucial for global eradication efforts.

Purpose of the Study:

  • To review clinical trials and studies on adjuvant TB immunotherapy.
  • To investigate the relationship between immune status and TB relapse or reactivation.
  • To evaluate the potential of targeting granulomas for improved TB treatment.

Main Methods:

  • Literature review of clinical trials for adjuvant TB immunotherapy.
  • Analysis of studies on immune status and TB relapse/reactivation.

Related Experiment Videos

  • Examination of anti-tumor necrosis factor (TNF) therapies and their impact on TB treatment.

    • Main Results:

    • Interferon therapy did not enhance macrophage mycobactericidal capacity.
    • Interleukin-2 delayed microbiologic response; anti-TNF therapies (prednisolone, etanercept) accelerated treatment response.
    • Anti-TNF antibody infliximab may target and disrupt granulomas by inducing apoptosis.
    • Accelerated TB treatment and reduced relapse risk were observed in HIV-coinfected individuals.

    Conclusions:

    • The granulomatous response may protect sequestered mycobacteria from anti-TB therapy.
    • Therapeutic disruption of granulomas could improve TB treatment outcomes.
    • Further clinical trials are warranted to test granuloma-targeting strategies for TB treatment.